CytoSorbents Q3 revenue rises on growth in distributor and partner sales

By Reuters News


Overview

  • US blood purification firm's Q3 revenue rose 3% yr/yr, led by distributor and partner sales

  • Company achieved operating cash flow breakeven, reflecting cost cuts and higher gross margin

  • Adjusted EBITDA loss improved by 86% yr/yr


Outlook

  • Company aims to sustain operating cash flow at or near breakeven while investing to accelerate sales growth

  • CytoSorbents prioritizes restoring growth in Germany and expanding international sales

  • Company expects to submit new De Novo application for DrugSorb-ATR to FDA in early 2027


Result Drivers

  • MANUFACTURING EFFICIENCIES - Manufacturing efficiencies and improved sourcing expanded product gross margin to 75%

  • DISTRIBUTOR SALES GROWTH - Distributor and strategic partner sales rose 16% yr/yr

  • COST REDUCTIONS - Operating expenses fell 11% due to lower headcount and expense management


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$9.73 mln

$9.91 mln (2 Analysts)

Q3 Loss Per Share

$0.58

Q3 Gross Margin

75%


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Cytosorbents Corp is $15.00, about 180.9% above its November 11 closing price of $5.34


Reuters Recommended Reads

  • Nov 12 - NeuroPace Q3 revenue misses analyst estimates, dragged by account-level issues

  • Nov 12 - Sanara MedTech Q3 revenue misses estimates on soft tissue product sales

  • Nov 10 - Switzerland's Alcon Q3 sales slightly miss estimates despite surgical equipment launches, vision care growth


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.